A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity
Prashanth Kumar Bajpe(Cancer Genomics Centre), René Bernards(The Netherlands Cancer Institute)
Cited by 49
Related Papers
Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence
|Nature Cell Biology|2006|610
The Cancer SENESCopedia: A delineation of cancer cell senescence
|Cell Reports|2021|200
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
|Nature Communications|2020|91
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
|International Journal of Cancer|2014|75